"We are disappointed in the study outcome, and based on these data, we will be reevaluating our path forward for CCH for the treatment of adhesive capsulitis of the shoulder. We will continue focusing on our pipeline, including with respect to other potential CCH indications," said James P. Tursi, M.D., Executive Vice President, Global Research & Development at Endo. "We are committed to advancing our strategic priority of expanding and enhancing our portfolio for growth."
Day 95 visit, the difference compared to those study participants receiving placebo was not statistically significant.
ENDP
New York Yankees and Duke Basketball
